Company / PP&E (Net)
ELITE PHARMACEUTICALS INC /NV/ PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$10.3M
FY2025
5-year range
$6.0M / $10.4M
FY2021-FY2025
Trend
+1.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has fluctuated over the past 10 years, ranging from $6M in FY2022 to $10M in FY2023.
Based on SEC 10-K filings.
$10M in FY2025 with a 5-year CAGR of +7.4%.
Remained stable around $10M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +20.2%
- 5-Year CAGR
- +7.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +7.4%, indicating consistent growth.
- In FY2025, pp&e (net) increased 1.5% year-over-year.
- Peak pp&e (net) was recorded in FY2023.
- Lowest pp&e (net) in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.3M | +1.5% |
| FY2024 | $10.2M | -2.4% |
| FY2023 | $10.4M | +75.1% |
| FY2022 | $6.0M | -10.5% |
| FY2021 | $6.6M | -8.0% |
| FY2020 | $7.2M | -14.4% |
| FY2019 | $8.4M | -6.1% |
| FY2018 | $9.0M | -0.5% |
| FY2017 | $9.0M | +11.5% |
| FY2016 | $8.1M | +26.7% |
As of FY2025 · SEC 10-K · Updated Jun 29, 2026